

下記の研究テーマについても提案を募集しています。(4/22(月)まで)

- Understanding tumor heterogeneity and resistance (innate and acquired resistance to targeted agents or resistance to chemotherapy): including single cell analyses of treatment resistant tumors, studies with persistent tumor cells and studies of minimal residual disease
- Identification of driver oncogenic & immune pathways and effects of pharmacological modulation in preclinical models, particularly explants, representative of the following cancers; EGFRm NSCLC, Gastric cancer (GC), Hepatocellular carcinoma (HCC), Biliary tract carcinoma (BTC), Esophageal cancer, Head and neck cancer, and EBV positive related cancers
- New disease models: including studies with immunocompetent mouse models, new hematological cancer models, preclinical models of CDK4/6 and PARP resistance and PDXs in 1st line Osimertinib resistance
- New combinations with novel agents
- Translational science studies using CT-DNA
- Understanding key metabolic pathways and dependencies in the following cancers; EGFRm NSCLC, Gastric cancer (GC), Hepatocellular carcinoma (HCC), and Biliary tract carcinoma (BTC), Esophageal cancer, Head and neck cancer, and EBV positive related cancers. (HCC, GC would be of particular interest)



◆ 提供可能な化合物

Compound	Mechanism of Action
AZD5363 (Capiwasertib)	AKT serine/threonine protein kinase (also known as protein kinase B alpha) inhibitor
AZD9150 (Danvatirsen)	Signal transducer and activator of transcription 3 (STAT3) antisense
AZD1775	WEE1 G2 checkpoint kinase inhibitor
AZD4547	Fibroblast growth factor receptor (FGFR) tyrosine kinase family inhibitor
AZD5153	BRD4/BET bromodomain antagonist
AZD6738	Ataxia Telangiectasia and Rad3 related (ATR) serine/threonine protein kinase inhibitor
AZD4635	Adenosine A2A receptor (A2AR) antagonist
AZD1390	Ataxia telangiectasia mutated (ATM)-BBB
AZD2811	Aurora B serine/threonine kinase inhibitor
AZD0466	BCL2/xL inhibitor (nanomedicine)
AZD4573	Cyclin-dependent kinase 9 (CDK9) inhibitor
AZD7648	DNA-dependent protein kinase (DNA-PK) inhibitor
AZD5991	BH3-mimetic Myeloid cell leukemia 1 (MCL1) inhibitor
AZD9833	Selective estrogen receptor degrader (SERD)
AZD0095	Oral Monocarboxylate transporter 4 (MCT4) inhibitor

